Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas

Next Previous
Search
Trial Profile

Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Temozolomide (Primary) ; Carboplatin; Cisplatin; Etoposide
  • Indications Gastric cancer; Neuroendocrine carcinoma; Pancreatic cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 18 Mar 2025 Planned primary completion date changed from 30 Jun 2025 to 30 Sep 2025.
    • 10 Dec 2024 Planned primary completion date changed from 1 Jan 2025 to 30 Jun 2025.
    • 08 Jan 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top